An assessment of the effect of 1 dose with oxymetazoline nasal spray(Otrivin®) on the physical capacity of patients suffering from Chronic Obstructive Pulmonary Disease (COPD)
Key facts
- Where
- Loerenskog, NorvégiaSee the site
- Phase
- 3. fázis
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Norvégia
- Akershus University HospitalLoerenskog, NorvégiaToborzás még nem indult
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sorlandet Sykehus HF
- Trial code
- EU 2024-520177-12-00
- Record updated
- 2025. január 24.
- Original description
To assess the effect of 1 dose with oxymetazoline nasal spray(Otrivin®) on the physical capacity of patients suffering from Chronic Obstructive Pulmonary Disease (COPD)Read full original descriptionShow less
A single group treatment, phase 4, study to assess the effect of 1 dose with oxymetazoline nasal spray(Otrivin®) on physical capacity of males and females aged 18 and 64 years suffering from Chronic Obstructive Pulmonary Disease (COPD)
To assess the effect of 1 dose with oxymetazoline nasal spray(Otrivin®) on the physical capacity of patients suffering from Chronic Obstructive Pulmonary Disease (COPD)
Inclusion: Participants who comply with the standard diagnostic criteria for Chronic Obstructive Pulmonary Disease, COPD, as defined in the GOLD standard (Shireen M. 2028).
Exclusion: Active malignant disorders; Other obstructive pulmonary disorders; Pragnancy.